Next Article in Journal
Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer
Previous Article in Journal
Quality of Life and Symptoms of Hospitalized Hematological Cancer Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 31
Issue 11
10.3390/curroncol31110495
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea

by
Hyeong In Ha
1,2,†,
Hyung Joon Yoon
1,3,†,
Changho Song
4,
Eun Taeg Kim
5,
Dong-Soo Suh
1,3,
Ki Hyung Kim
1,3,
Yong Jin Na
1,2 and
Yong Jung Song
1,2,*
1
Department of Obstetrics and Gynecology, Pusan National University College of Medicine, Busan 49241, Republic of Korea
2
Department of Obstetrics and Gynecology, Pusan National University Yangsan Hospital, Yangsan-si 50612, Republic of Korea
3
Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea
4
Department of Obstetrics and Gynecology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Republic of Korea
5
Department of Obstetrics and Gynecology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan 49267, Republic of Korea
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Curr. Oncol. 2024, 31(11), 6711-6722; https://doi.org/10.3390/curroncol31110495
Submission received: 22 September 2024 / Revised: 15 October 2024 / Accepted: 22 October 2024 / Published: 28 October 2024
(This article belongs to the Section Gynecologic Oncology)
Browse Figures
Review Reports Versions Notes

Abstract

Purpose: In this study, we aimed to retrospectively investigate the real-world clinical efficacy and adverse events of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in real-world clinical practice among patients with newly diagnosed epithelial ovarian cancer. Methods: We retrospectively reviewed the medical records from hospitals. Patients with epithelial ovarian cancer treated with olaparib or niraparib as frontline maintenance treatment between 1 January 2014 and 31 December 2022 were included. Progression-free survival (PFS) was analyzed using the Kaplan–Meier method, and adverse events associated with PARP inhibitor treatment were investigated. Results: Ninety-six patients treated with PARP inhibitors were identified. The median follow-up period was 21.8 months (95% confidence interval [CI] 19.4–24.0). Twenty (20.1%) patients experienced disease progression, and two patients died. The median PFS was 45.3 months (95% CI 39.4–NA). BRCA1 or BRCA2 gene mutations and primary cytoreductive surgery were associated with better PFS. Adverse events of any grade occurred in 74 (77.1%) patients. Nineteen (19.8%) patients experienced PARP inhibitor therapy interruptions, and 35 (36.5%) patients experienced dose reductions. Only three patients discontinued the drug due to adverse events. Conclusions: In a real-world setting, PARP inhibitors showed efficacy comparable to that reported in published randomized controlled trials and had acceptable safety profiles.
Keywords: ovarian cancer; PARP inhibitor ovarian cancer; PARP inhibitor

Share and Cite

MDPI and ACS Style

Ha, H.I.; Yoon, H.J.; Song, C.; Kim, E.T.; Suh, D.-S.; Kim, K.H.; Na, Y.J.; Song, Y.J. Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea. Curr. Oncol. 2024, 31, 6711-6722. https://doi.org/10.3390/curroncol31110495

AMA Style

Ha HI, Yoon HJ, Song C, Kim ET, Suh D-S, Kim KH, Na YJ, Song YJ. Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea. Current Oncology. 2024; 31(11):6711-6722. https://doi.org/10.3390/curroncol31110495

Chicago/Turabian Style

Ha, Hyeong In, Hyung Joon Yoon, Changho Song, Eun Taeg Kim, Dong-Soo Suh, Ki Hyung Kim, Yong Jin Na, and Yong Jung Song. 2024. "Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea" Current Oncology 31, no. 11: 6711-6722. https://doi.org/10.3390/curroncol31110495

APA Style

Ha, H. I., Yoon, H. J., Song, C., Kim, E. T., Suh, D.-S., Kim, K. H., Na, Y. J., & Song, Y. J. (2024). Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea. Current Oncology, 31(11), 6711-6722. https://doi.org/10.3390/curroncol31110495

Article Metrics

Back to TopTop